Globotriosylceramide · SMALL MOLECULE · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Globotriosylceramide shows approved-linked disease relevance led by Fabry disease. 3 linked drugs keep the current disease frame grounded. Use Fabry disease as the disease frame, then confirm a stable protein accession before cross-source reuse.
Use Fabry disease as the disease frame, then confirm a stable protein accession before cross-source reuse.
Globotriosylceramide shows approved-linked disease relevance led by Fabry disease. 3 linked drugs remain visible in the same block.
Start review with Fabry disease because it currently carries approved-linked support. Linked drugs include AGALSIDASE ALFA, AGALSIDASE BETA, PEGUNIGALSIDASE ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGlobotriosylceramide
Review this target as Globotriosylceramide.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Globotriosylceramide as ChEMBL target CHEMBL2366040. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Globotriosylceramide still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need to confirm why Fabry disease is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Globotriosylceramide |
| Target Type | SMALL MOLECULE |
| Organism | Homo sapiens |
Reviewable protein naming and mapping context for this target snapshot.
Review this target as Globotriosylceramide.
Open Targets-ready disease context using the current target-indication evidence contract.
Globotriosylceramide shows approved-linked disease relevance led by Fabry disease.
Start review with Fabry disease because it currently carries approved-linked support. Linked drugs include AGALSIDASE ALFA, AGALSIDASE BETA, PEGUNIGALSIDASE ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.